Screener
Krystal Biotech, Inc. KRYS Business Segments — Net Income
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 7:06 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001711279-26-000043
| (in thousands, except per share data) | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Interest and other income, net | 7,753 | 7,345 |
| Income before income taxes | 61,442 | 43,597 |
| Income tax expense | (5,510) | (7,864) |
| Net income | 55,932 | 35,733 |
| Unrealized (loss) gain on available-for-sale securities | (1,577) | 344 |
| Foreign currency translation | (1,182) | 236 |
| Comprehensive income | $53,173 | $36,313 |
| Net income per common share: |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Krystal Biotech, Inc.'s business segments — net income?
- Krystal Biotech, Inc. (KRYS) reported business segments — net income of $55.93M in Q1 2026.
- How has Krystal Biotech, Inc.'s business segments — net income changed year-over-year?
- Krystal Biotech, Inc.'s business segments — net income increased by 56.5% year-over-year, from $35.73M to $55.93M.
- What is the long-term trend for Krystal Biotech, Inc.'s business segments — net income?
- Over 3 years (2022 to 2025), Krystal Biotech, Inc.'s business segments — net income has grown at a 13.5% compound annual growth rate (CAGR), from -$139.98M to $204.83M.
- What does business segments — net income mean?
- Net income is the final bottom-line profit or loss of the segment after all expenses, taxes, and non-operating items have been accounted for. It represents the ultimate financial result of the segment's activities for the reporting period.
Ask your AI about Krystal Biotech, Inc.'s business segments — net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude